Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.

Zinner RG, Nemunaitis J, Eiseman I, Shin HJ, Olson SC, Christensen J, Huang X, Lenehan PF, Donato NJ, Shin DM. Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res. 2007 May 15; 13(10):3006-14.

View in: PubMed